A new Mayo Clinic study has demonstrated new evidence of the link between the biology of aging and idiopathic pulmonary fibrosis (IPF). The study, “Cellular senescence mediates fibrotic pulmonary disease,” appeared in this month’s issue of Nature Communications and point towards new possible directions for therapies targeting IPF. “Idiopathic pulmonary fibrosis…
Mayo Clinic Study Links Biology of Aging and IPF, Opens New Paths for Possible Therapies
There’s a new online resource to help idiopathic pulmonary fibrosis (IPF) patients and their caregivers learn more about the condition and be more proactive in their treatment. Find out more about the future of pulmonary fibrosis treatment. The interactive program is a joint venture between the Pulmonary Fibrosis Foundation, ProPatient,…
I sat down to open my mail a few days ago and received what felt like a slap in the face. Shame hurts. My local utility company sent me a report letting me know that I was using 161 percent more…
When you have a chronic illness such as pulmonary fibrosis, it is only natural that you may find yourself spending a lot of time thinking about some of the important life events and milestones that you may not get to experience. Learn about the challenges patients with pulmonary fibrosis and…
In an article for Shape magazine, journalist Kylie Gilbert slams the use of cigarettes in fashion shoots featuring some of the world’s most recognizable celebrity models. Here are four things you can do to help prevent pulmonary fibrosis. A recent photo spread featuring reality stars and models Kendall…
With Rare Disease Day 2017 coming up tomorrow (Tuesday, Feb. 28), I have been thinking a lot about responsibility. As someone living with a rare disease (idiopathic pulmonary fibrosis, or IPF), I am feeling a bit of responsibility around my efforts to raise awareness for this disease, and…
Aeolus Pharmaceuticals has started a Phase 1 clinical trial to evaluate a new version of AEOL 10150 as a treatment for delayed effects of acute lung radiation exposure(Lung-ARS). The open-label, single-center Phase 1 trial will evaluate the safety, tolerability and pharmacokinetics in healthy individuals of increasing doses of AEOL…
If you have a chronic illness like pulmonary fibrosis it’s easy to focus on the future instead of living your life in the moment. What’s the future of pulmonary fibrosis treatment? Find out more. Our resident columnist Kim Fredrickson knows this all too well and in her latest article “Don’t Let Your Diagnosis…
PBI-4050 is a safe and effective therapy for patients with idiopathic pulmonary fibrosis (IPF), according to results of the now-completed Phase 2 clinical trial developed by ProMetic Life Sciences. The open-label, single-arm, Phase 2 study (NCT02538536) enrolled 40 IPF patients at six different sites in Canada to investigate the safety,…
I always have been fairly independent. When I was little I played outside alone in a small town where the “scary stories” of a big city just didn’t happen. I was lucky enough to buy my first car very early in my teenage years, which gave me…
